JADPRO Resource Center – Biomarkers in NSLC: Quiz #1

Which of the following are the main targetable pathways in NSCLC?
EGFR, PI3K/AKT/mTOR, RAS-MAPK, NTRK/ROS1
EGFR, PD-L1, RAS-MAPK, NTRK/ROS1
VEGF, PI3K/AKT/mTOR, RAS-MAPK, NTRK/ROS1
VEGF, EGFR, RAS-MAPK, NTRK/ROS1
EGFR mutations account for approximately what percentage of patients with NSCLC adenocarcinomas in the US?
23%
31%
15%
5%
EGFR mutations are more common in smokers.
True
False
Entrectinib is approved for treating which of the following NSCLC driver oncogenes?
ALK
ROS1
EGFR
BRAF
Tyrosine kinase inhibitors are able to target specific proteins that play important roles in tumor growth and progression.
True
False
{"name":"JADPRO Resource Center – Biomarkers in NSLC: Quiz #1", "url":"https://www.poll-maker.com/QZ963Q8DD","txt":"Which of the following are the main targetable pathways in NSCLC?, EGFR mutations account for approximately what percentage of patients with NSCLC adenocarcinomas in the US?, EGFR mutations are more common in smokers.","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}
Tools: Poll Maker | Quiz Maker | Super Surveys